{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T08:05:16Z","timestamp":1773389116669,"version":"3.50.1"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA125123"],"award-info":[{"award-number":["P30CA125123"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA126752"],"award-info":[{"award-number":["P50CA126752"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"CPRIT","doi-asserted-by":"publisher","award":["RP160283"],"award-info":[{"award-number":["RP160283"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia & Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001552","name":"Cancer Research Trust New Zealand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001552","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003463","name":"Haematology Society of Australia and New Zealand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003463","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000043","name":"American Association for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000043","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.coi.2021.09.009","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T04:24:56Z","timestamp":1637123096000},"page":"46-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Beyond CD19 CAR-T cells in lymphoma"],"prefix":"10.1016","volume":"74","author":[{"given":"Wingchi K","family":"Leung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adanma","family":"Ayanambakkam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7049-7698","authenticated-orcid":false,"given":"Helen E","family":"Heslop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LaQuisa C","family":"Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2021.09.009_bib0005","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3389\/fonc.2020.00849","article-title":"CAR T-cell therapy for B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia: clinical trials and real-world experiences","volume":"10","author":"Vitale","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.coi.2021.09.009_bib0010","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/17474086.2017.1270202","article-title":"Diagnostic, prognostic and therapeutic role of CD30 in lymphoma","volume":"10","author":"Pierce","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.coi.2021.09.009_bib0015","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.85","article-title":"Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions","volume":"7","author":"van der Weyden","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.coi.2021.09.009_bib0020","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2021.09.009_bib0025","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2015.65.4194","article-title":"Evaluation of the risk of relapse in classical Hodgkin lymphoma at event-free survival time points and survival comparison with the general population in British Columbia","volume":"34","author":"Hapgood","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coi.2021.09.009_bib0030","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1038\/bmt.2016.257","article-title":"Outcomes of Hodgkin lymphoma patients who relapse after allogeneic stem cell transplantation","volume":"51","author":"Castagna","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.coi.2021.09.009_bib0035","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","article-title":"Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: an open-label phase I trial","volume":"23","author":"Wang","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.coi.2021.09.009_bib0040","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41408-020-0274-9","article-title":"Anti-CD30 chimeric antigen receptor T cell therapy for relapsed\/refractory CD30(+) lymphoma patients","volume":"10","author":"Wang","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.coi.2021.09.009_bib0045","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1172\/JCI94306","article-title":"Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes","volume":"127","author":"Ramos","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coi.2021.09.009_bib0050","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coi.2021.09.009_bib0055","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/j.1398-9995.1997.tb00177.x","article-title":"In vivo relevance of CD30 in atopic dermatitis","volume":"52","author":"Caproni","year":"1997","journal-title":"Allergy"},{"key":"10.1016\/j.coi.2021.09.009_bib0060","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/mt.2015.197","article-title":"Evaluation of TCR gene editing achieved by TALENs, CRISPR\/Cas9, and megaTAL nucleases","volume":"24","author":"Osborn","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.coi.2021.09.009_bib0065","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-019-0801-y","article-title":"Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions","volume":"12","author":"Fleischer","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.coi.2021.09.009_bib0070","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","article-title":"An \u201coff-the-shelf\u201d fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies","volume":"32","author":"Cooper","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.coi.2021.09.009_bib0075","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2014-10-567461","article-title":"The biology and management of systemic anaplastic large cell lymphoma","volume":"126","author":"Hapgood","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.coi.2021.09.009_bib0080","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coi.2021.09.009_bib0085","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.coi.2021.09.009_bib0090","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1200\/JCO.2013.54.2456","article-title":"Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study","volume":"32","author":"Fanale","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coi.2021.09.009_bib0095","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.1182\/bloodadvances.2020003218","article-title":"Long-term remission in multiply relapsed enteropathy-associated T-cell lymphoma following CD30 CAR T-cell therapy","volume":"4","author":"Voorhees","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.coi.2021.09.009_bib0100","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1182\/blood-2015-02-629527","article-title":"A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies","volume":"126","author":"Mamonkin","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.coi.2021.09.009_bib0105","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies","volume":"130","author":"Gomes-Silva","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.coi.2021.09.009_bib0110","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1038\/leu.2017.8","article-title":"Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor","volume":"31","author":"Chen","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.coi.2021.09.009_bib0115","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s12015-019-09937-9","article-title":"Characterization of an anti-CD5 directed CAR T-cell against T-cell malignancies","volume":"16","author":"Wada","year":"2020","journal-title":"Stem Cell Rev Rep"},{"key":"10.1016\/j.coi.2021.09.009_bib0120","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood-2019-129559","article-title":"Safety and anti-tumor activity of CD5 CAR T-cells in patients with relapsed\/refractory T-cell malignancies","volume":"134","author":"Hill","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.coi.2021.09.009_bib0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2019.12.482","article-title":"CD5 CAR T-cells for treatment of patients with relapsed\/refractory CD5 expressing T-cell lymphoma demonstrates safety and anti-tumor activity","volume":"26","author":"Hill","year":"2020","journal-title":"Biol Blood Marrow Transplantation"},{"key":"10.1016\/j.coi.2021.09.009_bib0130","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s12015-020-10092-9","article-title":"Treatment of aggressive T cell lymphoblastic lymphoma\/leukemia using anti-CD5 CAR T cells","volume":"17","author":"Feng","year":"2021","journal-title":"Stem Cell Rev Rep"},{"key":"10.1016\/j.coi.2021.09.009_bib0135","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1158\/1078-0432.CCR-20-1271","article-title":"Eradication of T-ALL cells by CD7-targeted universal CAR-T cells and initial test of ruxolitinib-based CRS management","volume":"27","author":"Li","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.coi.2021.09.009_bib0140","series-title":"American Society of Hematology 62nd Annual Meeting","article-title":"First-in-class autologous CD7-CAR-T cells exhibited promising clinical efficacy for relapsed and refractory T-lymphpblastic leukemia\/lymphoma","author":"Zhang","year":"2020"},{"key":"10.1016\/j.coi.2021.09.009_bib0145","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.bbmt.2010.03.014","article-title":"Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20\/CD19-specific chimeric antigen receptor redirected T cells in humans","volume":"16","author":"Jensen","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.coi.2021.09.009_bib0150","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1182\/blood-2011-10-387969","article-title":"CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results","volume":"119","author":"Till","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.coi.2021.09.009_bib0155","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.clim.2014.10.002","article-title":"Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells","volume":"155","author":"Wang","year":"2014","journal-title":"Clin Immunol"},{"key":"10.1016\/j.coi.2021.09.009_bib0160","doi-asserted-by":"crossref","first-page":"17054","DOI":"10.1038\/sigtrans.2017.54","article-title":"Long-term safety and efficacy of CART-20 cells in patients with refractory or relapsed B-cell non-Hodgkin lymphoma: 5-years follow-up results of the phase I and IIa trials","volume":"2","author":"Zhang","year":"2017","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.coi.2021.09.009_bib0165","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial","volume":"26","author":"Shah","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2021.09.009_bib0170","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1365-2567.2007.02752.x","article-title":"CD22: an inhibitory enigma","volume":"123","author":"Walker","year":"2008","journal-title":"Immunology"},{"key":"10.1016\/j.coi.2021.09.009_bib0175","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/384634a0","article-title":"CD22 regulates thymus-independent responses and the lifespan of B cells","volume":"384","author":"Otipoby","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.coi.2021.09.009_bib0180","first-page":"4052","article-title":"Phase I immunotoxin trial in patients with B-cell lymphoma","volume":"51","author":"Vitetta","year":"1991","journal-title":"Cancer Res"},{"key":"10.1016\/j.coi.2021.09.009_bib0185","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.3324\/haematol.2017.183459","article-title":"Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma","volume":"103","author":"Shalabi","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.coi.2021.09.009_bib0190","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1182\/blood.2020009432","article-title":"CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma","volume":"137","author":"Baird","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.coi.2021.09.009_bib0195","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1097\/CJI.0b013e3180de5d90","article-title":"Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction","volume":"30","author":"Turatti","year":"2007","journal-title":"J Immunother"},{"key":"10.1016\/j.coi.2021.09.009_bib0200","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1016\/j.ymthe.2017.06.008","article-title":"Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase","volume":"25","author":"Walker","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.coi.2021.09.009_bib0205","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1016\/j.bbmt.2019.06.036","article-title":"Understanding and managing large B cell lymphoma relapses after chimeric antigen receptor T cell therapy","volume":"25","author":"Byrne","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.coi.2021.09.009_bib0210","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1172\/JCI86000","article-title":"Clinical responses with T lymphocytes targeting malignancy-associated kappa light chains","volume":"126","author":"Ramos","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coi.2021.09.009_bib0215","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1182\/bloodadvances.2018029678","article-title":"Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma","volume":"3","author":"Koksal","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.coi.2021.09.009_bib0220","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood-2018-04-842708","article-title":"Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas","volume":"132","author":"Scarfo","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.coi.2021.09.009_bib0225","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41375-020-0792-2","article-title":"CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression","volume":"35","author":"Fousek","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.coi.2021.09.009_bib0230","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-021-01282-6","article-title":"Base-edited CAR T cells for combinational therapy against T cell malignancies","author":"Georgiadis","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.coi.2021.09.009_bib0235","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13045-019-0746-1","article-title":"Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies","volume":"12","author":"Wang","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.coi.2021.09.009_bib0240","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2016-09-738245","article-title":"PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR","volume":"129","author":"Chong","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.coi.2021.09.009_bib0245","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/s41409-019-0657-3","article-title":"Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen receptor T-cell therapy in refractory diffuse large B-cell lymphoma","volume":"55","author":"Hill","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.coi.2021.09.009_bib0250","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1182\/blood-2018-10-882944","article-title":"Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia","volume":"133","author":"Sanchez-Martinez","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.coi.2021.09.009_bib0255","doi-asserted-by":"crossref","first-page":"112783","DOI":"10.18632\/oncotarget.22626","article-title":"Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells","volume":"8","author":"Pinz","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.coi.2021.09.009_bib0260","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.3324\/haematol.2018.192757","article-title":"CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia","volume":"104","author":"Naik","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.coi.2021.09.009_bib0265","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1182\/blood-2010-04-278218","article-title":"T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies","volume":"117","author":"Shaffer","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.coi.2021.09.009_bib0270","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/nm.4444","article-title":"Targeting the T cell receptor beta-chain constant region for immunotherapy of T cell malignancies","volume":"23","author":"Maciocia","year":"2017","journal-title":"Nat Med"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095279152100128X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095279152100128X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T08:46:12Z","timestamp":1760604372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095279152100128X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":54,"alternative-id":["S095279152100128X"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2021.09.009","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond CD19 CAR-T cells in lymphoma","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2021.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}